Morgan Stanley Reaffirms Their Hold Rating on 4D Molecular Therapeutics (FDMT)
I'm PortAI, I can summarize articles.
Morgan Stanley analyst Judah Frommer has reaffirmed a Hold rating on 4D Molecular Therapeutics (FDMT), with shares closing at $10.17. The analyst consensus for the stock is Strong Buy, with a price target of $34.43, indicating a potential upside of 238.54%. Another report from TR | OpenAI also maintained a Hold rating with a price target of $10.50. Frommer has an average return of 0.9% and a 55.02% success rate on his stock recommendations.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments